A Study of LY3437943 in Postmenopausal Female Participants Who Are Overweight or Obese

Phase 1 study, condition: Overweight. The main purpose of this study is to determine the effect of LY3437943 when administered subcutaneously on the levels of combined oral contraceptive (COC) ethinyl estradiol and drospirenone in the blood stream in postmenopausal female participants who are overweight or obese. The safety and tolerability of LY3437943 when administered with COC will also be evaluated. This study will last up to approximately 29 weeks for each participant. Enrolment: 46 participants. Status: completed. No topline or peer-reviewed results are verified for publication on this Record for this study — registry facts only.